Core Insights - Kraig Biocraft Laboratories, Inc. is expanding its research and development capacity to support the rapid progress of its advanced materials initiative, Project Atlas [1][4] Group 1: Expansion of R&D Capacity - The company has enhanced its laboratory capabilities by onboarding new scientific personnel and deploying advanced equipment, which has tripled screening throughput [3][5] - These upgrades were implemented in response to the rapid technical advancements made under Project Atlas, which focuses on creating advanced biomaterials for industrial and defense applications [4][5] Group 2: Screening and Analytical Improvements - The newly commissioned equipment streamlines the screening of transgenic lines and analyzes spider silk expression levels, allowing for the identification of new production material candidates [5][6] - Enhanced analytical testing capabilities provide deeper insights into the expression levels and functional impacts of engineered transgenic lines, enabling the prioritization of promising genetic designs for production [6][8] Group 3: Leadership and Recognition - The company's leadership in bioengineering was highlighted on the cover of the March 2026 issue of National Geographic, emphasizing the significance of its work in scaling spider silk production [9]

Core Viewpoint - OR Royalties Inc. has appointed Mr. Patrick Godin as an Independent Director to its Board of Directors, bringing extensive experience in the mining industry to the company [1][3]. Group 1: Appointment Details - Mr. Godin has over 35 years of corporate, technical, and operational experience in the mining industry, most recently serving as President and CEO of New Gold Inc. [2] - His leadership at New Gold included overseeing the company during its US$7.0 billion acquisition by Coeur Mining, Inc. [2] - Mr. Godin has held various senior positions in other mining companies, including Pretivm Resources Inc. and Stornoway Diamond Corporation, where he was responsible for significant mining operations [2]. Group 2: Company Overview - OR Royalties is a precious metals royalty and streaming company focused on Tier-1 mining jurisdictions, including Canada, the United States, and Australia [4]. - Since its inception in June 2014, the company has grown its portfolio to over 195 royalties, streams, and similar interests, anchored by a 3-5% net smelter return royalty on Agnico Eagle Mines Limited's Canadian Malartic Complex [4].

Core Insights - Ocugen, Inc. is set to host a conference call and live webcast on March 24, 2026, to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy, a late-stage dry age-related macular degeneration [1] Group 1: Company Overview - Ocugen, Inc. is a biotechnology leader specializing in gene therapies for blindness diseases, utilizing a modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [3] - The company is developing programs for inherited retinal diseases and blindness diseases affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [3] Group 2: Conference Details - Key opinion leaders participating in the webcast include Dr. Victor H. Gonzalez and Dr. Syed M. Shah, who will answer questions during the event [2] - Attendees can join the call using specific dial-in numbers for U.S. and international callers, with a conference ID provided for access [2] - A replay of the call and archived webcast will be available on the Ocugen investor site following the event [2]

Core Viewpoint - Alm. Brand Group has received an upgrade in its ESG rating from 'A' to 'AAA', marking it as an industry leader in ESG performance [1]. Group 1: ESG Rating Upgrade - The upgrade to 'AAA' reflects the collective efforts of the entire organization [2]. - This rating reaffirms Alm. Brand Group's commitment to sustainable value creation for stakeholders [2]. Group 2: Corporate Social Responsibility - Corporate social responsibility is a core pillar of Alm. Brand Group's overall strategy towards 2028 [1].

Core Viewpoint - Brunswick Exploration Inc. has successfully completed a non-brokered private placement, raising a total of $5,445,000 through the issuance of 20,780,000 units, which will be used to accelerate international exploration plans and support ongoing projects in Quebec [1][2][3]. Financing Details - The company issued an additional 5,000,000 units at a price of $0.25 per unit, generating gross proceeds of $1,250,000 [1]. - Each unit consists of one common share and one half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at $0.35 for 36 months [3]. - The total gross proceeds from the offering amount to $5,445,000 [2]. Use of Proceeds - The net proceeds from the offering will be allocated for exploration activities in Canada, Saudi Arabia, and Greenland, as well as for general corporate purposes and working capital [4]. Finder's Fees - The company paid finder's fees totaling $278,200 and issued 490,000 non-transferable finder warrants, each exercisable at $0.25 for a period of 24 months [5]. Regulatory Compliance - The offering was completed under the listed issuer financing exemption, allowing the units to be offered without resale restrictions in Canada [6]. Company Overview - Brunswick Exploration is focused on grassroots lithium exploration in Canada, Greenland, and Saudi Arabia, with a significant project portfolio including the Mirage project, which has an inferred mineral resource estimate of 52.2 million tonnes grading 1.08% Li2O [9].

Core Viewpoint - PyroGenesis Inc. has launched its plasma-based SPARC™ system at New Zealand's National Refrigerant Destruction Facility, marking a significant advancement in environmental stewardship by safely destroying hazardous refrigerants locally, thus reducing greenhouse gas emissions [1][3][10]. Group 1: Facility and Technology - The National Refrigerant Destruction Facility is the first of its kind in the Southern Hemisphere, capable of destroying up to 100,000 kg of hazardous synthetic refrigerants annually [1][3]. - The SPARC™ system utilizes an all-electric steam plasma arc technology to safely eliminate ozone-depleting refrigerants, providing a cleaner alternative to traditional incineration methods [8][10]. - The facility is strategically located near geothermal plants, allowing it to utilize renewable energy for its operations, promoting a sustainable closed-loop system [4]. Group 2: Environmental Impact - The destruction of these refrigerants, which have a combined Global Warming Potential equivalent to 220 million kilograms of CO2, is crucial for mitigating climate change [1][3]. - One kilogram of HFC refrigerant, such as R-410A, has a greenhouse effect comparable to 2,000 kg of CO2, highlighting the importance of the facility in addressing climate impact [10]. - The initiative aims to eliminate the need for transporting hazardous materials to Australia for incineration, thereby streamlining logistics and enhancing environmental safety [3][4]. Group 3: Financial Aspects - PyroGenesis was awarded a contract valued at approximately $6 million for the design and construction of the SPARC™ system for New Zealand [3]. - The project is part of a national initiative to tackle the climate impact of harmful refrigerant gases, indicating potential for future growth and investment opportunities in environmental technologies [3][10]. Group 4: Industry Context - The facility addresses the growing reliance on synthetic refrigerants across various sectors, including air conditioning, healthcare, and logistics, emphasizing the need for effective end-of-life solutions [6]. - PyroGenesis leverages over 35 years of plasma technology expertise to provide advanced engineering solutions, positioning itself as a leader in the environmental services sector [12].

Core Viewpoint - Public Policy Holding Company, Inc. (PPHC) has announced the acquisition of Westminster Policy Partners Limited (WPI Strategy), enhancing its advisory and economics capabilities in the UK market, with the transaction expected to close around April 1, 2026 [1][3]. Transaction Overview - WPI Strategy, founded in 2014, specializes in research-driven advocacy, combining communications and policy advisory with in-house economics capabilities [3]. - In the twelve months leading to January 2026, WPI Strategy generated approximately £2.45 million in net revenue and employs around 14 professionals [4]. - The firm has received accolades such as 'Consultancy of the Year' by City AM and recognition from PR Week for its role in the Vodafone and Three merger [4]. Strategic Rationale - The acquisition aligns with PPHC's goal of building a portfolio of complementary strategic communications businesses, enhancing its ability to deliver integrated policy, communications, and reputation advisory services [6]. - WPI Strategy's model combines policy advisory, economic modeling, impact analysis, and communications strategy, grounded in quantitative evidence [6]. - The transaction strengthens PPHC's presence in the UK, following its acquisition of Pagefield in 2024, and will create a platform with over 60 client-facing professionals [7]. Financial Impact - The acquisition is expected to be immediately earnings accretive and aligns with PPHC's target margin profile, enhancing organic growth prospects and long-term shareholder value [7][9]. Leadership and Integration - All employees and advisers of WPI Strategy will transition to PPHC, retaining their trading brand and operating as the economics and policy consulting unit within Pagefield Group [5]. - Nick Faith and Sean Worth will join Pagefield's Senior Leadership Team, reinforcing the integration of WPI Strategy into PPHC's operations [5]. Market Positioning - The acquisition is seen as a disciplined growth strategy, adding differentiated capabilities that combine economic evidence, policy advocacy, and strategic communications [10]. - PPHC aims to leverage this acquisition to enhance its service offerings in the UK and Europe, providing comprehensive solutions to its clients [10][11].

Core Insights - Nasdaq and Talos have formed a partnership to integrate Talos' digital asset infrastructure with Nasdaq's Calypso and Trade Surveillance platforms, aiming to create a unified solution for managing tokenized collateral [1][4] - The integration addresses barriers to the adoption of tokenized collateral in institutional markets, particularly the challenges of incorporating digital assets into existing risk management and collateral workflows [1][2] Group 1: Tokenized Collateral - Tokenized collateral represents traditional financial assets on distributed ledger technology, facilitating real-time mobility of securities and cash equivalents across platforms, unlocking trapped capital and enhancing operational efficiency [2] - A Nasdaq report indicates that 25% of collateral is currently immobilized in non-interest-bearing measures, amounting to over $35 billion in excess collateral, highlighting the need for infrastructure to manage tokenized collateral effectively [2] Group 2: Integration Benefits - Talos provides institutional-grade digital asset capabilities, while Nasdaq Calypso is a leading platform for managing risk and collateral across mainstream asset classes, allowing for integrated management of on- and off-chain collateral workflows [3] - The partnership aims to enhance institutional connectivity to marketplaces and custodians, facilitating a more cohesive operational environment for market participants [3] Group 3: Market Integrity and Compliance - The partnership will enable Talos clients to access Nasdaq Trade Surveillance, which detects potential market abuse across both mainstream and digital asset markets, ensuring institutional-grade oversight [6][8] - Clients will benefit from sophisticated detection alerts for suspicious trading patterns, which are essential for maintaining market integrity as digital assets grow [7][8]

Core Viewpoint - Curative Biotechnology, Inc. has announced a 1-for-150 reverse stock split to strengthen its capital structure and enhance investor awareness while advancing its clinical development strategy for novel treatments in degenerative eye diseases [1][9]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 1.02 billion to about 6.8 million shares, maintaining ownership percentages for shareholders with minor adjustments for fractional shares [2]. - Shares held through the Depository Trust Company (DTC) will decrease from approximately 266.8 million to around 1.78 million shares, which are eligible for electronic trading [3]. Group 2: Clinical Development Strategy - Curative is advancing its metformin-based ophthalmology platform and is pursuing a manufacturing and product development agreement for sterile metformin ophthalmic drops to support initial clinical studies [4]. - The first-in-human clinical study is planned at the National Institutes of Health (NIH) for treating dry Age-Related Macular Degeneration (AMD) [5]. - The initial K9 target indication is for PDE6-associated retinal degeneration in dogs, which may qualify for the Center for Veterinary Medicine's conditional approval pathway [6]. - A successful K9 study could provide support for developing metformin-based formulations targeting human Retinitis Pigmentosa [7]. - Manufacturing is expected to commence in mid-April 2026, with a facility capable of performing required stability testing [7]. Group 3: Strategic Direction and Future Plans - The company aims to submit an application to uplist its common stock to the OTCQB Venture Market, which requires higher financial reporting standards and corporate governance [10][11]. - Management is evaluating potential strategic relationships to support clinical development objectives and increase awareness among institutional investors [9].

Core Insights - Convex Group Limited ("Convex") demonstrated strong financial performance in 2025, with Gross Premium Written increasing by 14% and Net Premium Earned rising by 20% year-over-year [2] - The company achieved a robust underwriting result with a combined ratio of 89%, benefiting from an improved expense ratio as it scales [2] - Convex's net income surged by 40% to $711 million in 2025, compared to $506 million in 2024 [2] Financial Performance - Gross Premium Written increased by 14% year-over-year [2] - Net Premium Earned rose by 20% year-over-year [2] - Combined ratio stood at 89%, indicating effective underwriting performance [2] - Net income for 2025 reached $711 million, a 40% increase from the previous year [2] Investment and Ownership - Onex Corporation invested $3.8 billion in Convex on February 6, 2026 [3] - Onex holds a 63% equity stake in Convex, indicating significant ownership and influence [6]